Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02631408
Other study ID # iVRCT1_4
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date August 2015
Est. completion date March 1, 2021

Study information

Verified date March 2021
Source Orthopedic Hospital Vienna Speising
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Vancomycin powder (for solution for Infusion) will be investigated (off-label usage) in spinal fusion surgery. The powder will be locally administered into to the wound cavity before wound closure. Hypothesis: Locally applied vancomycin powder leads to a reduction in postoperative surgical site infections


Description:

Vancomycin is being widely used as an antibiotic agent for intravenous and topical use. The surgical application of vancomycin powder in Austria is limited as there is no powder with marketing authorization for intraoperative, intrawound usage. Previous reports widely document the application of vancomycin powder for solution for infusion. The powder is not soluted, but instead directly spread throughout the wound surface. Limited data is available for spinal fusion surgery, mostly retrospective studies. Results were promising, but the low evidence level does not allow for a conclusion regarding routine usage. Additional randomized, controlled trials are necessary to further investigate this matter. This trial aims to investigate Vancomycin powder "Xellia" 1000mg, which has a Marketing authorization, in an off-label usage (intrawound, intraoperatively) in spinal fusion surgery. The investigational medicinal product will be used unmodified.


Recruitment information / eligibility

Status Completed
Enrollment 308
Est. completion date March 1, 2021
Est. primary completion date March 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Planned TLIF (transforaminal lumbar interbody fusion) or PLIF (posterolateral lumbar interbody fusion) surgery - TLIF/PLIF fusion length of one or two motion-segments OR - One motion-segment TLIF/PLIF in conjunction with one motion-segment decompression surgery or microscopic disc surgery (microdiscectomy) - Fusions within L1 (first lumbar vertebra) through S1 (sacrum) - Age of 18-years or older - Signed informed consent Exclusion Criteria: - Preoperative inflammatory or infectious state (C-reactive protein levels above 10mg/l) - Allergic to vancomycin, teicoplanin or penicillin - Preexisting auto-immune disease with an impaired immune system - Current post-traumatic vertebral injury (e.g. vertebral split fracture) - Preexisting Renal impairment - Preexisting cochlea damage - Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Vancomycin
Locally, intrawound applied vancomycin powder

Locations

Country Name City State
Austria Orhopedic Hospital Speising Vienna

Sponsors (1)

Lead Sponsor Collaborator
Orthopedic Hospital Vienna Speising

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary SSI rate Rate of superficial and deep surgical site infections (according to CDC criteria) 1 year
Secondary C-reactive protein Course of postoperative CRP levels 7 days
Secondary Revision rate Revision rate due to surgical site infections 1 year
See also
  Status Clinical Trial Phase
Completed NCT00808665 - Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion Phase 4
Recruiting NCT02466048 - Efficacy and Safety of SurgiFillâ„¢ on Spinal Fusion Phase 4